HSBC Turns Bullish on Adobe: $308 Price Target Signals 46% Upside
The upgrade highlights Adobe’s resilience to AI disruption and its attractive valuation.
NOTRELOAD AI
Quantum Pure-Play Infleqtion Sparks Analyst Optimism with Canaccord Buy Rating and 70% Upside
Highlighting neutral-atom tech leadership, CHIPS Act funding, and 2026 revenue guidance of $40M+.
Morgan Stanley Upgrades Grindr to Overweight, Sees 25% Upside on AI and Telehealth Push
New Edge AI tier and Woodwork telehealth expected to drive strong revenue growth.
TD Cowen Boosts TransMedics Price Target to $120 on Strong Transplant Growth
Accelerating U.S. heart, liver & lung transplants plus strong flight data signal major growth ahead.
Short Seller Culper Attacks Tarsus Pharmaceuticals Over XDEMVY Market Size
Culper Research argues Tarsus is significantly overvalued, disputing the addressable market for its Demodex blepharitis drug XDEMVY.
Guardant Health Shares Surge as UnitedHealthcare Covers Shield Blood Test
UnitedHealthcare will begin reimbursing Guardant Health’s Shield colorectal cancer blood test from August 1, driving strong investor reaction and broader commercial access.